The treatment with mTOR inhibitors (everolimus, sirolimus) is effective for cardiac rhabdomyomas of TSC [32,33], and the Japanese Society of Tuberous Sclerosis has published an “Expert opinion consensus for everolimus treatment” (http://jstsc.kenkyuukai.jp/information/information_detail.asp?id=98767 (in Japanese), last accessed on 27 August 2022). The gene discussed is MTOR; the disease is cardiac rhabdomyoma.